Get alerted when price crosses intrinsic value.

Pfizer Inc.Opportunity Rank #219(PFE) Intrinsic Value & DCF Analysis (2026)

Sector: Healthcare

Current Price

$25.08

Last updated: Jun 23, 2026

Price vs Intrinsic Value

$25.08

Price

$26.21

Intrinsic Value

Undervalued by 5%MOS: $20.97

Fundamental Score

32/100

Bearish

Weighted across 6 signals

Narrative Score

63/100

Improving

+1 vs previous

Trend Score

31/100

Weak

As of 2026-06-22

The intrinsic value of Pfizer Inc. (PFE) is estimated at $26.21 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $25.08, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 0.25% long-term growth rate and an 8.50% discount rate (calculated: 6.63%), reflecting expected future free cash flow and cost of capital.

Valuation Details

$26.21

▲ 4.51% upside

20% margin of safety: $20.97

Years: 10Growth Rate: 0.25%Discount Rate: 8.50%

Want to create your own valuation? Create a free account.

Capital Efficiency

Average Quarterly ROIC

1.85%

Cost of Capital (estimated)9%

Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with.

Fundamental Details

32/100

BearishWeighted across 6 signals

DCF Discount

4.5% discount to price

FCF Yield

10.1% trailing FCF yield

100

ROIC vs WACC

ROIC 1.9% vs WACC 9.0% (0.2x)

Net Debt / FCF

3.5x net debt to FCF

Buybacks

Share count growing

FCF CAGR (5Y)

-1.8% 5Y FCF CAGR (adjusted)

Strengths: FCF Yield. Concerns: ROIC vs WACC, Net Debt / FCF.

Narrative Details

63/100

Improving

+1 vs previous · +2 new driversVs 6-Month Baseline:Low (5th pct)Weighted across 6 recent drivers

Trend: Deteriorating downConfidence: 100%Updated: 3h ago

Sources: 200 (194 News · 6 Analyst)

Drivers(last 30 days)

171 news sentiment+0.5

4 earnings beat+0.3

5 legal risk+0.3

12 regulatory scrutiny+0.2

Analyst upgrades+0.1

Restructuring-0.0

Trend Details

31/100

WeakAs of 2026-06-22308 daily bars used

3M Relative Strength vs SPY-21.8%

6M Relative Strength vs SPY-10.7%

Distance from 52-Week High-12.2%

Price vs 21 EMA33 · -2.8%

Price vs 50 EMA31 · -3.9%

21 EMA vs 50 EMA40 · -1.2%

3M RS vs SPY3 · -21.8%

6M RS vs SPY23 · -10.7%

Distance from 52W High76 · -12.2%

Investment Coach

Updating... 12d ago

AVOIDConfidence: 54%

Thesis

Pfizer Inc. shows a supportive narrative with an improving trend and a healthy free cash flow yield of 9.9%, but its fundamentals are weak with returns trailing the estimated cost of capital. The stock is slightly undervalued with a fair value upside of about 5.8%, yet the overall fundamental score remains bearish.

Key Risk

The key risk is Pfizer's return on invested capital significantly underperforming its weighted average cost of capital, indicating value destruction.

Signals To Watch

Price moving to at least a mid-teens discount to fair value.
Sustained improvement in ROIC versus WACC spread.
Meaningful shifts in the narrative score direction.

Ask the Coach - Available with

Historical Growth Rates

Free Cash Flow- - -Trend CAGR: 0.25%5 Year CAGR (Adjusted): -10.26%

Free Cash Flow (in millions)

TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
$14,486	$14,334	$15,653	$12,607	$32,503	$35,291	$17,194	$15,182	$18,023	$18,687	$17,900	$16,008	$18,466	$19,230	$18,381	$21,900	$12,967	$17,792	$19,939	$15,233	$19,644

How Intrinziq Estimates Fair Value

Intrinziq estimates Pfizer Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Pfizer Inc.Healthcare

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.